KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 99 filers reported holding KEROS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,264,054 | +9.1% | 71,018 | +37.5% | 0.00% | 0.0% |
| Q2 2023 | $2,075,659 | +72273.0% | 51,659 | -23.1% | 0.00% | 0.0% |
| Q1 2023 | $2,868 | -8.6% | 67,169 | +2.8% | 0.00% | 0.0% |
| Q4 2022 | $3,137 | -99.9% | 65,339 | +1.0% | 0.00% | 0.0% |
| Q3 2022 | $2,433,000 | +39.9% | 64,693 | +2.8% | 0.00% | 0.0% |
| Q2 2022 | $1,739,000 | -43.5% | 62,940 | +4.0% | 0.00% | 0.0% |
| Q1 2022 | $3,076,000 | +3.4% | 60,495 | -4.7% | 0.00% | 0.0% |
| Q4 2021 | $2,974,000 | +42.1% | 63,477 | -6.8% | 0.00% | 0.0% |
| Q3 2021 | $2,093,000 | -57.3% | 68,102 | -41.0% | 0.00% | 0.0% |
| Q2 2021 | $4,904,000 | -35.9% | 115,465 | -7.1% | 0.00% | -50.0% |
| Q1 2021 | $7,650,000 | +14.1% | 124,287 | +30.8% | 0.00% | 0.0% |
| Q4 2020 | $6,702,000 | +541.3% | 95,012 | +250.8% | 0.00% | – |
| Q3 2020 | $1,045,000 | +3.3% | 27,084 | +0.4% | 0.00% | – |
| Q2 2020 | $1,012,000 | – | 26,970 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |